Medtech titan Medtronic (NYSE:MDT) touted a new European regulatory win for its endovascular portfolio, announcing CE Mark and planning a global launch of the Sentrant introducer sheath.
The Sentrant device is designed for use with the company’s Endurant II AAA and Valiant Captivia stent graft systems, but also works with similar endovascular repair devices, according to the company.
Inserted at the femoral artery, the Sentrant is a tapered tube that a physician threads through the patient’s iliac arteries to facilitate implantation of a stent graft into the aorta. The new introducer comes in a range of sizes from 12 to 26 French and 28 to 64 cm, according to a press release.
The new approval marks 2 regulatory wins for Medtronic this month alone. Earlier this week the company announced FDA clearance of its Affinity Fusion blood oxygenation system.